axitinib plus toripalimab

DRUG3 trials

Sponsors

Peking Union Medical College Hospital, ZHOU FANGJIAN, Hebei Medical University Fourth Hospital

Conditions

Biliary Tract NeoplasmsHepatobiliary NeoplasmLiver NeoplasmNeoadjuvantOligometastatic Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma

Phase 2

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Peking Union Medical College HospitalBiliary Tract Neoplasms, Hepatobiliary Neoplasm, Liver Neoplasm

Start: 2020-05-01End: 2024-06-30Target: 60Updated: 2023-03-29

SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma

RecruitingNCT07744932

Hebei Medical University Fourth HospitalOligometastatic Clear Cell Renal Cell Carcinoma

Start: 2026-08-15End: 2029-12-30Target: 48Updated: 2026-08-04

Phase 3

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

RecruitingNCT05738694

ZHOU FANGJIANNeoadjuvant, Renal Cell Carcinoma

Start: 2023-04-19End: 2027-12-31Target: 298Updated: 2026-03-17

Related Papers

A multicenter randomized controlled clinical study of neoadjuvant combination of axitinib plus toripalimab to improve disease-free survival of patients with renal cell carcinoma.

Journal of Clinical Oncology2026-05-28